Skip to main content
Clinical Trials/JPRN-UMIN000041321
JPRN-UMIN000041321
Recruiting
Phase 4

emborexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study - Lemborexant for insomnia in patients with psychiatric disorder

Fujita Health University School of Medicine0 sites100 target enrollmentAugust 5, 2020
ConditionsInsomnia

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Insomnia
Sponsor
Fujita Health University School of Medicine
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 5, 2020
End Date
March 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Fujita Health University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The following exclusion criteria will be applied: taking any sleeping pills other than ramelteon, zolpidem, zopiclone, or eszopiclone at baseline; contraindication to suvorexant; patients with coma; addiction to psychostimulants or alcohol; pregnancy or breastfeeding; neurological or systemic diseases; and anyone considered inappropriate to participate by the attending physician. We will not include any patient who received benzodiazepines before the study because sleeping pills other than the Z drugs (zolpidem, zopiclone, or eszopiclone) or ramelteon.

Outcomes

Primary Outcomes

Not specified

Similar Trials